Purchase Order 36C25621P0766
Award Date
3/18/21
Potential Completion Date
3/17/22
Potential Value
$145K
Federal Agency
Veterans Integrated Service Network 16
Awardee
Accredo Health Group, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit specialty pharmacy company. The contract is for a 180-day supply of the medication Uptravi 600mcg, with a ceiling value of $78,557.34. The contract is not designated as a set-aside. Accredo Health Group, Inc. is a key distributor of complex and high-value medications to the VA's Veterans Integrated Service Networks (VISNs), with a focus on drugs...
This is a $40,697.68 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of specialty pharmaceutical products, including medications to treat pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders. The contract has an ultimate completion date of March 14, 2025 and is part of the VA's Veterans...
The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price purchase order to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical product UPTRAVI. The $125,284.68 contract supports the delivery of this medication directly to VA medical centers and facilities across the country, including in Palo Alto, California. This order, which does not have a set-aside designation, is part of Accredo Health...
This is a federal contract award to Accredo Health Group, Inc., a prime contractor, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 21. The award is for the specialty medication UPTRAVI, with a potential value of $104,778.03 and a completion date of September 30, 2021. The contract is a firm fixed price purchase order with no set-aside designation. Accredo Health Group, a for-profit organization, provides specialty pharmacy...
This is a $32,078.04 firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a specialty pharmacy services provider. The contract, which does not have a set-aside designation, is for the delivery of various high-value medications to support the VA's healthcare services for veterans, including treatments for conditions such as pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders....
This is a $81,632.25 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit subsidiary of Express Scripts that specializes in providing specialty pharmaceutical services. The contract is for the delivery of the medication Tyvaso, which is used to treat pulmonary arterial hypertension. The contract has no set-aside designation and was awarded on April 6, 2021, with a completion date of September 30, 2021....
This is a $93,341.96 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the specialty pharmaceutical Tyvaso, which is used to treat pulmonary arterial hypertension. This contract is part of Accredo Health Group's ongoing work supporting the VA's Veterans Integrated Service Network (VISN) 21 with the distribution of specialty medications. The...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, for the delivery of the specialty pharmaceutical DUOPA. The $10,122.32 contract has a completion date of May 7, 2025 and was awarded on February 7, 2025 with no set-aside designation. Accredo Health Group, Inc., a subsidiary of Express Scripts, is a key distributor of complex and high-value medications, primarily...
The U.S. Department of Veterans Affairs (VA) awarded a $81,342.18 firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical TYVASO. The contract, which does not have a set-aside designation, is to support the VA's Veterans Integrated Service Network 21 (VISN 21) and has an ultimate completion date of September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and...
This firm fixed-price purchase order, valued at $8,906.37, was awarded by the National Institutes of Health (NIH) Clinical Center to Accredo Health Group, Inc., a specialty pharmacy services provider. The contract is for the delivery of specific medications, such as Uptravi, Tyvaso, and Oxervate, to support treatment programs for the Veterans Health Administration (VHA). Accredo is a subsidiary of Express Scripts and has an established role as a key pharmaceutical distributor in the VA's...